[18F]CTT1057

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Prostate CancerProstatic NeoplasmsRecurrence

Phase 2

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

CompletedNCT04838626

Novartis PharmaceuticalsProstate Cancer, Prostatic Neoplasms

Start: 2021-09-07End: 2023-11-24Updated: 2025-10-07

Phase 3

Study of Diagnostic Performance of [18F]CTT1057 in BCR

CompletedNCT04838613

Novartis PharmaceuticalsProstate Cancer, Prostatic Neoplasms, Recurrence

Start: 2021-09-30End: 2023-11-23Updated: 2025-10-20

Related Papers

Imaging Efficacy of [<sup>18</sup>F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study

Journal of Nuclear Medicine2025-06-052 citations

Imaging Efficacy of [<sup>18</sup>F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study

Journal of Nuclear Medicine2025-06-05